Format

Send to

Choose Destination
Lancet. 2019 May 11;393(10184):1937-1947. doi: 10.1016/S0140-6736(19)30772-X. Epub 2019 Apr 14.

Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial.

Collaborators (692)

Elbert A, Vallejos A, Alvarisqueta A, Maffei L, Juncos L, de Arteaga J, Greloni G, Farias E, Zucchini A, Vogel D, Cusumano A, Santos J, Fraenkel M, Gallagher M, Davis T, Acharya S, Cooke D, Suranyi M, Roger S, Toussaint N, Pollock C, Chan D, Stranks S, MacIsaac R, Endre Z, Schmidt A, Prager R, Mayer G, Warling X, Jadoul M, Hougardy J, Vercammen C, Van Vlem B, Gillard P, Costa E Forti A, Borges JL, Santos Canani L, Eliaschewitz F, Leite S, Fraige Filho F, Paschoalin R, Moura Neto JA, Deboni L, de Lourdes Noronha I, Cercato C, Prompt CA, Zanella M, Rassi N, D'Avila D, Milagres R, Felicio J, Pecoits Filho R, Riella MC, Salles J, Keitel E, Draibe S, Amodeo C, Youmbissi J, Roy L, Cournoyer S, Jolly S, Pichette V, Nesrallah G, Bajaj HS, Khandwala H, Aronson R, Goluch R, Tam P, Rabbat C, Tobe S, Bailey G, Chow S, Castillo A, Danin Vargas A, Gonzalez F, Munoz R, Gutierrez V, Godoy G, Zhao H, Liu Z, Zhao M, Guo X, Su B, Fu S, Xu Y, Yang J, Shi B, Xiao G, Shi W, Hao C, Xing C, Hou F, Luo Q, Li Y, Ji L, Zuo L, Wang S, Ni Z, Ding G, Chen N, Zhao J, Jia W, Yu S, Weng J, Xu G, Fu P, Sun S, Liu B, Ding X, Rychlik I, Oplustilova A, Bartaskova D, Honova V, Chmelickova H, Petr M, Bucek P, Tesar V, Zahumensky E, Povlsen J, Egstrup K, Oczachowska-Kulik A, Rossing P, Lahtela J, Strand J, Kantola I, Petit C, Combe C, Zaoui P, Esnault V, Urena Torres P, Halimi JM, Dussol B, Bieler T, Budde K, Dellanna F, Segiet T, Kosch C, Schmidt-Guertler H, Schenkenberger I, Vielhauer V, Pistrosch F, Alscher M, Hasslacher C, Hugo C, Muehlfeld A, Wanner C, Passadakis P, Apostolou T, Tentolouris N, Stefanidis I, Mavromatidis K, Liakopoulos V, Goumenos D, Siamopoulos K, Yeung V, Ozaki R, Fung S, Tan K, Tang S, Lui SL, Cheung SF, Sreenan S, Eustace J, O'Shea D, Lavin P, Stack A, Yagil Y, Wainstein J, Knobler H, Cohen J, Kenis I, Daoud D, Bar-Dayan Y, Frajewicki V, Adawi F, Gesualdo L, Santoro D, Marino F, Galfre A, Brunati C, Ruggenenti P, Rombola G, Pugliese G, Ravera M, Malberti F, Pontoriero G, Rampino T, De Cosmo S, Esposito C, Nappi F, Abaterusso C, Conte G, Panichi V, Lauro D, Capasso G, Russo D, Anzai J, Naka M, Ato K, Tsujimoto T, Nimura T, Nakashima E, Takeda T, Fujii S, Kobayashi K, Iwaoka H, Nagayama K, Harada H, Maeda H, Kishimoto R, Iitsuka T, Itabashi N, Furuya R, Maeda Y, Yamada D, Sasaki N, Sasaki H, Ueda S, Kashihara N, Watanabe S, Nakamura T, Kanai H, Makita Y, Ono K, Iehara N, Goto D, Kosuge K, Tsuchida K, Sato T, Sekikawa T, Okamoto H, Tanaka T, Ikeda N, Tadika T, Mukasa K, Osonoi T, Hirano F, Nishimura M, Yambe Y, Tanaka Y, Ujihara M, Sakai T, Imura M, Umayahara Y, Makino S, Nakazawa J, Yamaguchi Y, Kashine S, Miyaoka H, Suzuki K, Inoue T, Nagai S, Sato N, Yamamoto M, Taya N, Fujita A, Matsutani A, Shibagaki Y, Sato Y, Yamauchi A, Tsutsui M, Ishiko T, Kaneko S, Azuma N, Matsuda H, Hashiguchi Y, Onishi Y, Tokui M, Matsuhisa M, Kiyosue A, Shinoda J, Ishikawa K, Ahmad G, Vijayasingham S, Aziz NA, Hussein Z, Fung YK, Hassan WHHW, Wong HS, Goh BL, Ali NM, Merican NSYA, Vaithilingam I, Nik Ahmad NNF, Adam N, Sukor N, Vengadasalam VPP, Abdul Kadir K, Mohamed M, Renoirte Lopez K, Leguizamo-Dimas A, Chew Wong A, Chevaile-Ramos J, Gonzalez Gonzalez J, Rico Hernandez R, Nino-Cruz J, Sauque Reyna L, Gonzalez-Galvez G, Madero Rovalo M, Bochicchio-Ricardelli T, Aldrete J, Carranza-Madrigal J, Vogt L, Smak Gregoor P, Barendregt J, Luik P, Gansevoort R, Laverman G, Pilmore H, Lunt H, Baker J, Miller S, Rabindranath K, Zapata-Rincon L, Vargas-Gonzales R, Calderon Ticona J, Dextre Espinoza A, Burga Nunez J, Zea-Nunez CA, Herrada Orue B, Medina-Santander B, Delgado-Butron C, Farfan-Aspilcueta J, Mazur S, Necki M, Wruk M, Klodawska K, Popenda G, Skokowska E, Arciszewska M, Wiecek A, Ciechanowski K, Nowicki M, Birne R, Cabrita A, Ramos A, Antunes Ferreira MA, Matta Fontanet E, Alcantara-Gonzalez AA, Comulada-Rivera A, Galindo Ramos E, Cangiano J, Quesada-Suarez L, Calderon Ortiz R, Vazquez-Tanus J, Burgos-Calderon R, Rosado C, Hancu N, Pintilei E, Mistodie C, Bako G, Ionutiu L, Petrica L, Timar R, Tuta L, Duma L, Tutescu A, Ivanova S, Essaian A, Zrazhevskiy K, Tomilina N, Smolyarchuk E, Kuzin A, Lantseva O, Karpova I, Shamkhalova M, Liberanskaya N, Yavdosyuk A, Shvarts Y, Bardymova T, Blagoveshchenskaya O, Solovev O, Rechkova E, Pikalova N, Pavlova M, Kolmakova E, Sayfutdinov R, Villevalde S, Koziolova N, Martynenko V, Marasaev V, Maksudova A, Sigitova O, Mordovin V, Klimontov V, Samoylova Y, Karonova T, Yeoh LY, Teo BW, Foo MWY, Liew A, Tkac I, Oroszova A, Fekete J, Rosenberger J, Obetkova I, Fulopova A, Kolesarova E, Raslova K, Smolko P, Oksa A, Distiller L, Trokis J, Adams L, Makan H, Ramlachan P, Mitha E, Coetzee K, Punt Z, Bhorat Q, Naiker P, Ellis G, Van Zyl L, Lee KW, Kim MS, Yoo SJ, Yoon KH, Cho YW, Park TS, Kim SY, Choi MG, Oh TK, Lee KW, Shon HS, Suh SH, Kim BJ, Doo-Man K, Yi JH, Lee SA, Cho HC, Kim SG, Cha DR, Seo JA, Choi KM, Woo JT, Ahn KJ, Lee JH, Kim IJ, Lee MK, Jang HC, Park KS, Kim BS, Mok JO, Shin M, Yoon SA, Nam-Goong IS, Chung CH, Yu TY, Lee HW, Soto Gonzalez A, Almirall J, Egido J, Calero Gonzalez F, Fernandez Fresnedo G, Valera Cortes I, Praga Terente M, Garcia Mendez I, Navarro Gonzalez J, Herrero Calvo J, Cigarran Guldris S, Prieto Velasco M, Minguela Pesquera JI, Galan A, Pascual J, Marques Vidas M, Martins Munoz J, Rodriguez-Perez J, Castro-Alonso C, Bonet Sol J, Seron D, Fernandez Giraldez E, Arrieta Lezama J, Montero N, Hernandez-Jaras J, Santamaria Olmo R, Molas Coten JR, Hellberg O, Fellstrom B, Bock A, Pei D, Lin CL, Tien KJ, Chen CC, Huang CN, Jiang JY, Wu DA, Chu CH, Tseng ST, Chen JF, Bau CT, Sheu W, Wu MS, Sari R, Sezer S, Yildiz A, Satman I, Kalender B, Mankovskyy B, Fushtey I, Stanislavchuk M, Kolenyk M, Dudar I, Zolotaikina V, Abrahamovych O, Kostynenko T, Petrosyan O, Kuskalo P, Galushchak O, Legun O, Topchii I, Martynyuk L, Stryzhak V, Panina S, Tkach S, Korpachev V, Maxwell P, Gnudi L, Kon SP, Tindall H, Kalra P, Mark P, Patel D, El-Shahawy M, Bai L, Nica R, Lien YH, Menefee J, Busch R, Miller A, Ahmed A, Arif A, Lee J, Desai S, Bansal S, Bentsianov M, Belledonne M, Jere C, Gaona R, Greenwood G, Brusco O, Boiskin M, Belo D, Minasian R, Atray N, Lawrence M, Taliercio J, Pergola P, Scott D, Alvarez G, Marder B, Powell T, Bakdash W, Stoica G, McFadden C, Rendell M, Wise J, Jones A, Jardula M, Madu IJ, Varghese F, Tulloch B, Ahmed Z, Hames M, Nazeer I, Shahid N, John R, Montero M, Fitz-Patrick D, Phillips L, Guasch A, Christofides E, Gundroo A, Amin M, Bowman-Stroud C, Link M, Mulloy L, Nammour M, Lalwani T, Hanson L, Whaley-Connell A, Herman L, Chatha R, Osama S, Liss K, Kayali Z, Bhargava A, Israel E, Peguero-Rivera A, Fang M, Slover J, Barengolts E, Flores J, Muoneke R, Savin V, Awua-Larbi S, Levine A, Newman G, Golestaneh L, Bohm G, Reisin E, Cruz L, Weiss R, Zieve F, Horwitz E, Chuang P, Mersey J, Manley J, Graf R, Bedros F, Joshi S, Frias J, Assefi A, O'Shaughnessy A, Brantley R, Minga T, Tietjen D, Kantor S, Jamal A, Guadiz R, Hershon K, Bressler P, Kopyt N, Cathcart H, Bloom S, Reichel R, Nakhle S, Dulude E, Tarkan J, Baker P, Zeig S, Moya Hechevarria J, Ropero-Cartier A, De la Calle G, Doshi A, Saba F, Sligh T, Shaw S, Kumar J, Szerlip H, Bayliss G, Perlman A, Sakhrani L, Gouge S, Argoud G, Acosta I, Elder J, Joshi S, Sensenbrenner J, Vicks S, Mangoo-Karim R, Galphin C, Leon-Forero C, Gilbert J, Brown E, Ijaz A, Butt S, Markell M, Arauz-Pacheco C, Sloan L, Alvarado O, Jabbour S, Simon E, Rastogi A, James S, Bakris G, Hall K, Melish J, Dixon B, Adolphe A, Kovesdy C, Beddhu S, Solomon R, Fernando R, Levin E, Thakar C, Robey B, Goldfarb D, Fried L, Maddukuri G, Thomson S, Annand A, Kronfli S, Kalirao P, Schmidt R, Dahl N, Blumenthal S, Weinstein D, Ostergaard O, Weinstein T, Ono Y, Yalcin M, Karim S.

Erratum in

Abstract

BACKGROUND:

Short-term treatment for people with type 2 diabetes using a low dose of the selective endothelin A receptor antagonist atrasentan reduces albuminuria without causing significant sodium retention. We report the long-term effects of treatment with atrasentan on major renal outcomes.

METHODS:

We did this double-blind, randomised, placebo-controlled trial at 689 sites in 41 countries. We enrolled adults aged 18-85 years with type 2 diabetes, estimated glomerular filtration rate (eGFR) 25-75 mL/min per 1·73 m2 of body surface area, and a urine albumin-to-creatinine ratio (UACR) of 300-5000 mg/g who had received maximum labelled or tolerated renin-angiotensin system inhibition for at least 4 weeks. Participants were given atrasentan 0·75 mg orally daily during an enrichment period before random group assignment. Those with a UACR decrease of at least 30% with no substantial fluid retention during the enrichment period (responders) were included in the double-blind treatment period. Responders were randomly assigned to receive either atrasentan 0·75 mg orally daily or placebo. All patients and investigators were masked to treatment assignment. The primary endpoint was a composite of doubling of serum creatinine (sustained for ≥30 days) or end-stage kidney disease (eGFR <15 mL/min per 1·73 m2 sustained for ≥90 days, chronic dialysis for ≥90 days, kidney transplantation, or death from kidney failure) in the intention-to-treat population of all responders. Safety was assessed in all patients who received at least one dose of their assigned study treatment. The study is registered with ClinicalTrials.gov, number NCT01858532.

FINDINGS:

Between May 17, 2013, and July 13, 2017, 11 087 patients were screened; 5117 entered the enrichment period, and 4711 completed the enrichment period. Of these, 2648 patients were responders and were randomly assigned to the atrasentan group (n=1325) or placebo group (n=1323). Median follow-up was 2·2 years (IQR 1·4-2·9). 79 (6·0%) of 1325 patients in the atrasentan group and 105 (7·9%) of 1323 in the placebo group had a primary composite renal endpoint event (hazard ratio [HR] 0·65 [95% CI 0·49-0·88]; p=0·0047). Fluid retention and anaemia adverse events, which have been previously attributed to endothelin receptor antagonists, were more frequent in the atrasentan group than in the placebo group. Hospital admission for heart failure occurred in 47 (3·5%) of 1325 patients in the atrasentan group and 34 (2·6%) of 1323 patients in the placebo group (HR 1·33 [95% CI 0·85-2·07]; p=0·208). 58 (4·4%) patients in the atrasentan group and 52 (3·9%) in the placebo group died (HR 1·09 [95% CI 0·75-1·59]; p=0·65).

INTERPRETATION:

Atrasentan reduced the risk of renal events in patients with diabetes and chronic kidney disease who were selected to optimise efficacy and safety. These data support a potential role for selective endothelin receptor antagonists in protecting renal function in patients with type 2 diabetes at high risk of developing end-stage kidney disease.

FUNDING:

AbbVie.

PMID:
30995972
DOI:
10.1016/S0140-6736(19)30772-X
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center